Abstract
Treatment of diseases of the temporomandibular joint (TMJ), complicated by hypertension of the masticatory muscles, remains one of the unsolved problems of dentistry. The purpose of this clinical study is to assess the safety and efficacy of the first Russian botulinum toxin a (BTA) Relatox® for the correction of masticatory muscle hypertension in patients with myofascial pain syndrome, as well as its comparison with the Lantox® by these parameters. Injections of botulinum toxin type A are a method of treatment in patients with myofascial facial pain syndrome with high therapeutic potential. The analysis of clinical results of using the Russian botulinum toxin type A of Relatox® shows high clinical efficacy. Comparative analysis of Lantox® and Relatox® showed no differences in safety and efficacy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
